Atomoxetine in the Treatment of Binge Eating Disorder

Completed · Phase 4

Conditions studied: Binge-eating Disorder

In brief

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Key facts

Study ID

NCT00327834

Run by

Lindner Center of HOPE

Starts

2006-05-01

Expected to finish

2007-03-01

Last updated by the study team

2011-06-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
• In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

You may not qualify if…

• Have concurrent symptoms of bulimia nervosa or anorexia nervosa
• Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
• Patients who are displaying clinically significant suicidality or homicidality

Where it is running

• University of Cincinnati Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.